## HCV DRAG: Clinical Trial Design, Follow-up and Resistance: FDA and EMEA perspective

March 24, 2009 AGENDA

Meeting Location: Marriott Wardman Park Hotel 2660 Woodley Road, NW Washington, DC 20008 Wilson Room on the Mezzanine Level

2:00 PM	Lunch - Wilson Room (Mezzanine Level)	
15.00	Welcome & Introductions	Veronica Miller, Ann Kwong
15.00	Brief Recap of HepC HCV DRAG & Review of Meeting Goals	Dale Kempf
60.00	Panel Discussion: "Clinical Virology Lessons Learned with Respect to Resistance in Clinical Trials with Combinations Added to SOC; plus/minus IFN/Ribavarin and Lead-in Trial Design"	Moderator: Ann Kwong ; Panelists: Ann Kwong, Robert Ralston, Julian Symons, Gaston Picchio, Jules O'Rear
45.00	Clinical Trial Design: FDA & EMEA "Perspectives on Clinical Trials, including Definition of Treatment Experience" (brief presentations followed by panel discussion)	Moderator: Ira Jacobson ; Panelists: Jeffrey Murray, Nathalie Morgensztejn, Jules O'Rear
15.00	General Discussion	Veronica Miller, Dale Kempf (facilitators)
30.00	Break	
30.00	Long Term Follow up- Evolution of Variants in Patients with Drug Resistances: Lessons Learned in Setting Up a Registry and a Regulatory perspective	Robert Ralston, Jules O'Rear
15.00	General Discussion	Veronica Miller, Dale Kempf (facillitators)
45.00	discussion) combine with discussion on	Moderator: Jean-Michel Pawlotsky; Panelists: Geoff Dusheiko, Xavier Forns, Don Jensen, Ira Jacobson, Stuart Ray
15.00	Resistance Literature Repository Database	Tara Kieffer, Jim Sullivan
<b>1</b>		
	15.00 15.00 60.00 45.00 30.00 30.00 45.00	15.00 Welcome & Introductions  Brief Recap of HepC HCV DRAG & Review of Meeting Goals  Panel Discussion: "Clinical Virology Lessons Learned with Respect to Resistance in Clinical Trials with Combinations Added to SOC; plus/minus IFN/Ribavarin and Lead-in Trial Design"  Clinical Trial Design: FDA & EMEA "Perspectives on Clinical Trials, including Definition of Treatment Experience" (brief presentations followed by panel discussion)  15.00 General Discussion  30.00 Break  Long Term Follow up- Evolution of Variants in Patients with Drug Resistances: Lessons Learned in Setting Up a Registry and a Regulatory perspective  15.00 General Discussion  Trepatorogist & virologist Perspectives (panel discussion) combine with discussion on Patients Who Have Experienced Treatment Exiluses"